Due to their cost, however, coverage of GLP-1s for obesity treatment in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, and GLP-1 coverage in Medicare for treatment of obesity is prohibited under current law
How This Works AOD-9604 is a fragment of human growth hormone (hGH 176191) studied for its lipolytic (fat-mobilizing) activity intended to encourage fat breakdown without the blood-sugar or tissue-growth effects of full-length GH
Providers may be more cautious and order labs if you have kidney disease, heart issues, other chronic conditions, or if you are interested in more intensive or frequent IV treatments
Work in areas with a risk for infection, including day care centers, hospitals and sewage treatment plants
AOD 9604 for Targeted Fat Mobilization Originally developed as an anti-obesity drug, the AOD 9604 peptide is a fragment of the C-terminus of human growth hormone
OrderNow View Our Gallery The Awazul goal is to enhance our patients well-being and positive self-image